As for CML, studies focused on detecting mutations in BCR-ABL1 gene, because the fusion gene plays an important role in the pathogenesis of CML, and mutations in it might engender failure of one or more of the currently effective TKIs [13]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.